Tyrphostin A9 CAS: 10537-47-0

CAS NO: 10537-47-0
Malonoben Tyrphostin 9
Chemical Name: 3,4-Dihydroxybenzenemethanamine
Molecular Formula: C_8H_9NO_2
Formula Weight: 153.16 g/mol
CAS Number: 10537-47-0
Description Review
Description
Tyrphostin A9 has become a very intriguing chemical in the field of targeted therapeutic medicines. As a member of the tyrphostin family, it functions as a tyrosine kinase inhibitor, a class of drugs with tremendous promise in the treatment of different diseases, most notably cancer.




Popular Search Trend on Google
"Tyrphostin A9 is known for its ability to inhibit tyrosine kinase activity."
"Pharmacology of CAS 10537-47-0"
"Tyrphostin A9 cancer therapy"
"Exploring the molecular mechanism of Tyrphostin A9"
"Research studies on Tyrphostin A9"
"Tyrphostin A9, a tyrosine kinase inhibitor,"
"Therapeutic applications of Tyrphostin A9"
"Clinical trials for Tyrphostin A9"
"Modulation of the signal pathway of Tyrphostin A9"
"Researching the oncological properties of Tyrphostin A9."


Similar Products from Competitors
Other tyrosine kinase inhibitors, including Erlotinib, Imatinib, and Gefitinib, which target distinct aspects of tyrosine kinase activity in distinct oncological contexts, are found in the presence of Tyrphostin A9.


Health Advantages
Tyrphostin A9 may be useful in the treatment of disorders associated with aberrant tyrosine kinase activity due to its inhibitory effect on tyrosine kinases. This encompasses certain forms of cancer, in which it has the potential to prevent the development and multiplication of tumor elements.

Possible Consequences
The potential of Tyrphostin A9 to obstruct tyrosine kinase-mediated signaling pathways is one of its main effects. By interrupting these pathways, it may be possible to limit the mechanisms that contribute to uncontrolled cell proliferation in malignant tissues.

How the Product Works
The protein tyrosine kinase inhibitor tyrphostin A9 is responsible for its biological effects. By attaching to the enzyme, it does this, therefore inhibiting the transfer of a phosphate group from ATP to tyrosine residues on substrate proteins, which is an essential step in the process of information transmission.


Side Effects and Safety
Tyrphostin A9 is an experimental medication, hence research is still being done on its safety profile and adverse effects. Side effects are likely to be similar to those seen with other tyrosine kinase inhibitors, including exhaustion, skin rashes, and gastrointestinal difficulties.


Information on Dosing
Clinical trials, with an emphasis on determining the maximal tolerated dose and the effective therapeutic dose, will be utilized in the establishment of dosing guidelines for Tyrphostin A9.


Important considerations
First and foremost, if you have an allergy to Tyrphostin A9, you should not use it. During the course of clinical development, further limitations and precautions would be discovered.


In summary
Tyrphostin A9 may hold promise in fighting cancer and other tyrosine kinase-related disorders. The revolutionary trajectory of contemporary pharmacology is exemplified by its path from laboratory research to possible clinical use.

The Section "People Also Ask"
Q: Is Tyrphostin A9 presently utilized in clinical practice?
In response to your question, the answer is that Tyrphostin A9 is not yet licensed for clinical usage and is still in the process of being researched.

Concerning cancer research, what makes Tyrphostin A9 an important compound?
A: It is a very important molecule in cancer research because of its capacity to selectively inhibit certain tyrosine kinases. These kinases are crucial for the growth and advancement of several types of cancer.


How is Tyrphostin A9 different from other drugs that block tyrosine kinase?
A: Tyrphostin A9's selectivity and molecular structure may provide distinct pharmacokinetic and pharmacodynamic features when compared to other inhibitors, which may be critical in designing more effective and less harmful treatment choices.

What other things could Tyrphostin A9 be used for besides treating cancer?
Tyrphostin A9 is currently being studied mainly for its use in cancer therapy, but it may also have therapeutic promise in the treatment of various autoimmune illnesses, cardiovascular diseases, and other conditions involving tyrosine kinases.



  • Tyrphostin A9 tyrosine kinase inhibitor,
  • Tyrphostin A9 in cancer treatment,
  • Tyrosine kinase inhibition by Tyrphostin A9,
  • Tyrphostin A9 cellular signal transduction,
  • Cancer therapy with Tyrphostin A9,
  • Tyrphostin A9 and cell differentiation,
  • Tyrphostin A9 apoptosis regulation,
  • Tyrphostin A9 pharmacological effects,
  • Signal pathway disruption Tyrphostin A9,
  • Tyrphostin A9 clinical research.
    • "Tyrphostin A9 kinase inhibitor",
    • "Tyrphostin A9 cancer research",
    • "Tyrphostin A9 signal transduction",
    • "Tyrphostin A9 molecular mechanism",
    • "Tyrphostin A9 pharmacodynamics",
    • "Tyrphostin A9 clinical trials",
    • "Tyrphostin A9 therapeutic potential",
    • "Tyrphostin A9 in oncology",
    • "Tyrphostin A9 biochemical studies",
    • "Tyrphostin A9 cellular pathways".
  •  
Review
Review

ver_code
1/3
X
Send your message to us
please select your country
  • Afghanistan
  • Aland Islands
  • Albania
  • Algeria
  • American Samoa
  • Andorra
  • Angola
  • Anguilla
  • Antigua and Barbuda
  • Argentina
  • Armenia
  • Aruba
  • Australia
  • Austria
  • Azerbaijan
  • Bahamas
  • Bahrain
  • Bangladesh
  • Barbados
  • Belarus
  • Belgium
  • Belize
  • Benin
  • Bermuda
  • Bhutan
  • Bolivia
  • Bosnia and Herzegovina
  • Botswana
  • Bouvet Island
  • Brazil
  • British Indian Ocean Territory
  • British Virgin Islands
  • Brunei Darussalam
  • Bulgaria
  • Burkina Faso
  • Burundi
  • Cambodia
  • Cameroon
  • Canada
  • Cape Verde
  • Caribbean Netherlands
  • Cayman Islands
  • Central African Republic
  • Chad
  • Chile
  • China
  • Christmas Island
  • Cocos Islands
  • Colombia
  • Comoros
  • Congo
  • Cook Islands
  • Costa Rica
  • Cote D'ivoire
  • Cuba
  • Curaçao
  • Cyprus
  • Czech Republic
  • Democratic People's Republic of Korea
  • Democratic Republic of the Congo
  • Denmark
  • Djibouti
  • Dominica
  • East Timor
  • Ecuador
  • Egypt
  • El Salvador
  • Equatorial Guinea
  • Eritrea
  • Estonia
  • Ethiopia
  • Falkland Islands
  • Faroe Islands
  • Fiji
  • Finland
  • France
  • French Guiana
  • French Polynesia
  • French Southern Territories
  • Gabon
  • Gambia
  • Georgia
  • Germany
  • Ghana
  • Gibraltar
  • Greece
  • Greenland
  • Grenada
  • Guadeloupe
  • Guam
  • Guatemala
  • Guernsey
  • Guinea
  • Guinea-Bissau
  • Guyana
  • Haiti
  • Heard Island and Mcdonald Islands
  • Honduras
  • Hong Kong, China
  • Hungary
  • Iceland
  • India
  • Indonesia
  • Iran
  • Iraq
  • Ireland
  • Isle of Man
  • Israel
  • Italy
  • Jamaica
  • Japan
  • Jordan
  • Kazakhstan
  • Kenya
  • Kiribati
  • Korea
  • Kosovo
  • Kuwait
  • Kyrgyzstan
  • Laos
  • Latvia
  • Lebanon
  • Lesotho
  • Liberia
  • Liechtenstein
  • Lithuania
  • Luxembourg
  • Macau, China
  • Macedonia
  • Madagascar
  • Malawi
  • Malaysia
  • Maldives
  • Mali
  • Malta
  • Marshall Islands
  • Martinique
  • Mauritania
  • Mauritius
  • Mayotte
  • Mexico
  • Micronesia
  • Moldova
  • Monaco
  • Mongolia
  • Montenegro
  • Montserrat
  • Morocco
  • Mozambique
  • Myanmar
  • Namibia
  • Nauru
  • Nepal
  • Netherlands
  • Netherlands Antilles
  • New Caledonia
  • New Zealand
  • Nicaragua
  • Niger
  • Nigeria
  • Niue
  • Norfolk Island
  • Northern Mariana Islands
  • Norway
  • Oman
  • Pakistan
  • Palau
  • Palestine
  • Panama
  • Papua New Guinea
  • Paraguay
  • Peru
  • Philippines
  • Pitcairn Islands
  • Poland
  • Portugal
  • Puerto Rico
  • Qatar
  • Reunion
  • Romania
  • Russia
  • Rwanda
  • Saint Barthélemy
  • Saint Helena
  • Saint Kitts and Nevis
  • Saint Lucia
  • Saint Martin
  • Saint Pierre and Miquelon
  • Saint Vincent and the Grenadines
  • San Marino
  • Sao Tome and Principe
  • Saudi Arabia
  • Senegal
  • Serbia
  • Seychelles
  • Sierra Leone
  • Singapore
  • Sint Maarten
  • Slovakia
  • Slovenia
  • Solomon Islands
  • Somalia
  • South Africa
  • South Georgia and The South Sandwich Islands
  • Spain
  • Sri Lanka
  • State of Libya
  • Sudan
  • Suriname
  • Svalbard and Jan Mayen
  • Swaziland
  • Sweden
  • Switzerland
  • Syrian Arab Republic
  • TaiWan, China
  • Tajikistan
  • Tanzania
  • Thailand
  • The Republic of Croatia
  • Togo
  • Tokelau
  • Tonga
  • Trinidad and Tobago
  • Tunisia
  • Turkey
  • Turkmenistan
  • Turks and Caicos Islands
  • Tuvalu
  • Uganda
  • Ukraine
  • United Arab Emirates
  • United Kingdom
  • United States
  • United States Minor Outlying Islands
  • Uruguay
  • US Virgin Islands
  • Uzbekistan
  • Vanuatu
  • Vatican City State
  • Venezuela
  • Vietnam
  • Wallis and Futuna Islands
  • Western Sahara
  • Western Samoa
  • Yemen
  • Zambia
  • Zimbabwe
ver_code